U.S.-based, state-of-the-art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic.
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront